TTNP - Titan Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.50
-0.06 (-10.71%)
As of 3:58PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.56
Open0.56
Bid0.50 x 2200
Ask0.50 x 3100
Day's Range0.50 - 0.60
52 Week Range0.50 - 2.85
Volume632,445
Avg. Volume89,920
Market Cap10.602M
Beta1.36
PE Ratio (TTM)N/A
EPS (TTM)-0.53
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • Who Owns Titan Pharmaceuticals Inc (NASDAQ:TTNP)?
    Simply Wall St.6 hours ago

    Who Owns Titan Pharmaceuticals Inc (NASDAQ:TTNP)?

    If you want to know who really controls Titan Pharmaceuticals Inc (NASDAQ:TTNP), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions asRead More...

  • Titan Awarded NIDA Grant For The Development Of A Nalmefene Implant For The Prevention Of Opioid Addiction Relapse
    PR Newswire10 days ago

    Titan Awarded NIDA Grant For The Development Of A Nalmefene Implant For The Prevention Of Opioid Addiction Relapse

    SOUTH SAN FRANCISCO, Calif., Sept. 10, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has been awarded a two year grant of approximately $6.7 million from the National Institutes of Health's National Institute on Drug Abuse (NIDA) for the development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction, following opioid detoxification.  The grant provides approximately $2.7 million for the project from now through August 31, 2019, with the balance to be funded over the subsequent year, subject to satisfactory project progress, fund availability and certain other conditions. "NIDA previously provided funds for an important Phase 3 trial of our approved product, Probuphine®, and we are grateful for this additional vote of confidence in our ProNeura technology as well as our ability to execute on another program for the treatment of opioid addiction," said Titan's Chief Scientific Officer and Principal Investigator of the project, Dr. Kate DeVarney.

  • Why this Peninsula company needs a cash fix 2 years after opioid addiction treatment approved
    American City Business Journalslast month

    Why this Peninsula company needs a cash fix 2 years after opioid addiction treatment approved

    The drug-device is implanted in the arms of a limited scope of opioid abusers — and that's just one of Titan Pharmaceuticals' issues as it looks to be relaunch Probuphine in the United States on its own.

  • Associated Presslast month

    Titan Pharmaceuticals: 2Q Earnings Snapshot

    The San Francisco-based company said it had a loss of 4 cents per share. The specialty pharmaceutical company posted revenue of $2.7 million in the period. In the final minutes of trading on Tuesday, the ...

  • PR Newswirelast month

    Titan Pharmaceuticals Reports Second Quarter 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing ...

  • Titan Announces Amendment To Agreement With Molteni
    PR Newswire2 months ago

    Titan Announces Amendment To Agreement With Molteni

    SOUTH SAN FRANCISCO, Calif., Aug. 3, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) announced today that it has entered into an amendment (the "Amendment") of the previously announced definitive asset purchase, supply and support agreement (the "Purchase Agreement") with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni acquired the European intellectual property related to Probuphine®. Under the Amendment, Molteni will make an immediate payment to Titan of €950,000 (approx. $1.1 million), and has committed to make a convertible loan to Titan of €550,000 (approx. $0.6 million) in mid-September subject to Titan's submission, in accordance with the Amendment, of a response to questions posed by the European Medicines Agency (EMA), in exchange for the elimination of an aggregate of €2.0 million (approx. $2.3 million) of regulatory milestones provided for in the Purchase Agreement, which would be payable potentially in 2019 at the earliest.

  • Titan Pharmaceuticals Provides Update On Parkinson's Disease Clinical Development Program
    PR Newswire3 months ago

    Titan Pharmaceuticals Provides Update On Parkinson's Disease Clinical Development Program

    SAN FRANCISCO , July 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ ...

  • Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence
    PR Newswire4 months ago

    Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence

    SOUTH SAN FRANCISCO, Calif. and PLYMOUTH MEETING, Pa., May 30, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the United States and Canada. Under the terms of the termination agreement, Titan will regain all rights to the commercialization and clinical development of Probuphine in the U.S. and Canada. Braeburn has paid Titan $1 million and will provide assistance to Titan through December 28, 2018 to enable a smooth transition and ensure that patients and their doctors will continue to have support and access to this treatment.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of TTNP earnings conference call or presentation 16-May-18 8:15pm GMT

    Q1 2018 Titan Pharmaceuticals Inc Earnings Call

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 15) Inspire Medical Systems Inc (NYSE: INSP ) Aptevo Therapeutics ...

  • Associated Press4 months ago

    Titan Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the San Francisco-based company said it had a loss of 12 cents. The specialty pharmaceutical company posted revenue of $1.1 million in the period. In the final minutes of trading ...

  • Titan Pharmaceuticals Reports First Quarter 2018 Financial Results
    PR Newswire4 months ago

    Titan Pharmaceuticals Reports First Quarter 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif. , May 15, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing ...

  • Accomplished Global Pharmaceutical Executive, Federico Seghi Recli, Appointed To Titan's Board
    PR Newswire4 months ago

    Accomplished Global Pharmaceutical Executive, Federico Seghi Recli, Appointed To Titan's Board

    SOUTH SAN FRANCISCO, Calif. , May 14, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing ...

  • Titan Pharmaceuticals To Report First Quarter 2018 Financial Results On May 15, 2018
    PR Newswire4 months ago

    Titan Pharmaceuticals To Report First Quarter 2018 Financial Results On May 15, 2018

    Management Team to Host Conference Call the Following Day - May 16, 2018 - at 4:15 p.m. ET / 1:15 p.m. PT SOUTH SAN FRANCISCO, Calif. , May 8, 2018 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), ...

  • Zacks Small Cap Research5 months ago

    TTNP: Molteni Investment Relieves the Pressure

    The update caps a year with Probuphine revenues well below expectations. To address the weak sales by partner Braeburn, Titan began discussions to return commercialization rights. Due to the slow ramp of sales from Probuphine in the summer of 2017, Titan secured a debt facility from Horizon Technology Finance in July to fund the development programs in the pipeline.

  • ACCESSWIRE5 months ago

    Wired News – Conatus to Demonstrate Impact of Pan-caspase Inhibitor IDN-7314 in Reducing Inflammation and Liver Injury in Mouse Model of PSC at EASL Annual Meeting

    Stock Monitor: Titan Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Conatus Pharma Inc. (NASDAQ: CNAT ). If you ...

  • InvestorPlace6 months ago

    3 Stocks to Watch on Tuesday: Atlas Financial Holdings Inc (AFH), Eastside Distilling Inc (EAST) and Titan Pharmaceuticals, Inc. (TTNP)

    U.S. stocks plummeted Monday as the tech industry was hit hard and Amazon.com, Inc. (NASDAQ:AMZN) experienced a selloff, falling 5%. The S&P 500 Index fell 2.2%, the Dow Jones Industrial Average slid 1.9% and the Nasdaq Composite fell 2.7%.

  • ACCESSWIRE6 months ago

    Titan Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 2, 2018 / Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 2, 2018 at 4:15 PM Eastern ...

  • Associated Press6 months ago

    Titan Pharmaceuticals reports 4Q loss

    The San Francisco-based company said it had a loss of 17 cents per share. The specialty pharmaceutical company posted revenue of $58,000 in the period. For the year, the company reported a loss of $14.3 ...

  • Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results
    PR Newswire6 months ago

    Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

    Titan Management Team to Host Conference Call April 2 at 4:15 p.m. EDT / 1:15 p.m. PDT SOUTH SAN FRANCISCO, Calif. , April 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company ...

  • Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2017 Financial Results
    PR Newswire6 months ago

    Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2017 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 26, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced that it will host a live conference call at 4:15 p.m. ET / 1:15 p.m. PT on Monday, April 2, 2018 to discuss the company's financial results as of December 31, 2017. The call can also be accessed by dialing 1-855-940-9476 (or 1-412-317-5223 from outside the U.S.) five minutes prior to the start time, and asking to be joined into the Titan Pharmaceuticals, Inc. call. An audio recording of the call will also be archived on the Titan website.

  • Benzinga6 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Guess?, Inc. (NYSE: GES ) stock gained more than 11 ...

  • Titan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select Territories
    PR Newswire6 months ago

    Titan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select Territories

    SOUTH SAN FRANCISCO, Calif., March 21, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) announced today that it has entered into a definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni has acquired the European intellectual property related to Probuphine, including the Marketing Authorization Application (MAA) under review by the European Medicines Agency (EMA), and will have the exclusive right to commercialize the Titan supplied Probuphine product in Europe, as well as certain countries of the Commonwealth of Independent States, the Middle East and North Africa (the "Molteni Territory").

  • Titan Announces Amendment To Horizon Loan Agreement
    PR Newswire8 months ago

    Titan Announces Amendment To Horizon Loan Agreement

    SOUTH SAN FRANCISCO, Calif., Feb. 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced its entry into an amendment to the July 2017 loan agreement with Horizon Technology Finance Corporation. Pursuant to this amendment, Titan will prepay $3 million of the outstanding $7 million principle amount, with an additional $1 million prepayment due on the earlier of (i) Titan's receipt of cash proceeds of at least $5 million from the sale of equity or (ii) May 14, 2018.  Titan will also provide Horizon with a lien on its intellectual property, which will be released if Titan receives at least $500,000 in aggregate license revenues from sales of Probuphine® in the U.S. and Canada during any consecutive 12-month period prior to December 31, 2019.